Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.

Guidelines folder-tashatuvango-stock.adobe.com.jpeg

New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia

By Karen Jacobson-Sive

December 2nd 2024

Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.

New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com

Tattoos May Be Associated With Increased Risk of Rare NHLs

By AJMC Contributor

November 29th 2024

Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.

Big Data | Image Credit: © Friends Stock-stock.adobe.com

Real-World Data Confirm Ibrutinib's Role in Relapsed CLL

By Gayle Turim Dickstein

November 26th 2024

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.

Older woman taking out dose of pills from glass bottle | Image Credit: © fizkes - stock.adobe.com

Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles

By Jared Kaltwasser

November 23rd 2024

The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or refractory chronic lymphocytic leukemia (CLL).

<1 2 3 4

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions